Comparison of the outcome of conventional osteosarcoma at two specialist international orthopaedic oncology centres

Sarcoma

Volumn 8, Issue 1, 2004, Pages 13-18

  Ford, Samuel ^a   Saithna, Adnan ^a   Grimer, Robert J ^a   Picci, Piero ^b  

^a ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Osteosarcoma; Prognostic factors; Survival

Indexed keywords

ALKALINE PHOSPHATASE;

ADOLESCENT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER CONTROL; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; ITALY; KAPLAN MEIER METHOD; KNEE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; ONCOLOGY; ORTHOPEDICS; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SPECIALIST INTERNATIONAL ORTHOPEDIC ONCOLOGY CENTER; TREATMENT OUTCOME; TUMOR NECROSIS; UNITED KINGDOM;

EID: 1842453756     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577140410001679202     Document Type: Article

References (27)

1. Souhami RL, Craft AW, Van der Eijken, et al. Randomised trial of two regimes of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997; 350: 911-7.
2. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment for non-metastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997; 15: 6-84.
3. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with non-metastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000; 18: 4016-27.
4. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of the Cooperative German/Austrian study. J Clin Oncol 1984: 2: 617-24.
5. Saeter G, Wiebe T, Wiklund T, et al. Chemotherapy in osteosarcoma the Scandinavian Sarcoma Group experience. Acta Orthop Scand 1999; 70 (Suppl 285): 74-82.
6. Bacci G, Ferrari S, Mercuri M, et al. Neoadjuvant chemotherapy for extremity osteosarcoma: preliminary results of the Rizzoli's 4th study. Ann Oncol 1998; 37: 41-8.
7. Whelan JS. Paediatric update: Osteosarcoma. Eur J Cancer 1997; 33: 1611-9.
8. Saeter G, Elomaa I, Wahlqvist Y, et al. Prognostic factors in bone sarcomas. Acta Orthop Scand 1997; 68 (Suppl 273): 156-60.
9. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994; 12: 423-31.
10. Classer DB, Lane JM, Huvos AG, et al. Survival, prognosis and therapeutic response in osteogenic sarcoma. Cancer 1992; 69: 698-708.
11. Bacci G, Picci P, Ferrari S, et al. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer 1993; 71(4): 1224-30.
12. Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol 1990; 8: 1988-97.
13. Bielack SS, Kempf-Bielack B, Delling G, et al Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an anlysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-90.
14. Bacci G, Picci P, Ferrar S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993; 72: 3227-38.
15. Grimer RJ, Taminiau AM, Cannon SR. Surgical outcomes in osteosarcoma. J Bone Joint Surg 2002; 84-B: 395-400.
16. Bramwell VHC, Burgers M, Sneath R, et al. comparison of two short intensive intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European osteosarcoma Intergroup. J Clin Oncol 1992; 10: 1579-91.
17. Statview. Berkely, CA. Abacus Concepts, 1996.
18. Bacci G, Ferrari S, Lari S, et al. Osteosarcoma of the limb. J Bone Joint Surg 2002; 84B: 88-92.
19. Weeden S, Grimer RJ, Cannon SR, Taminiau AM, Uscinska BM. The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer 2001; 37: 39-46.
20. Picci P. Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrence. J Clin Oncol 1994; 12: 2699-705.
21. Picci P, Sangiorgi L, Bahamonde L, et al. Risk factors for local recurrence after limb-salvage surgery for high grade osteosarcoma of the extremities. Ann Oncol 1997; 8: 899-903.
22. Bacci G, Ferrari S, Mercuri M, et al. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumours followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand 1998; 69: 230-6.
23. Spanier SS, Shuster JJ, Vander Griend RA. The effect of local extent of the tumour on prognosis in osteosarcoma. J Bone Joint Surg 1990; 72A: 643-53.
24. Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PC. Does the histological subtype of high grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 2002; 38: 1218-25.
25. Taylor WF, Ivins JC, Pritchard DJ, et al. Trends and variability in survival among patients with osteosarcoma: a 7-year update. Mayo Clin Proc 1985; 60: 91-104.
26. Rosen G, Tau L, Sanmaneechai, et al. Rationale for multi-drug chemotherapy in the treatment of osteogenic sarcoma. Cancer 1975; 35: 936-45.
27. Sulzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80. J Cancer Res Clin Oncol 1983;106 (Suppl): 21-4.